	US 11,883,476 B2
	Canine lyme disease vaccine
Rhonda LaFleur, Omaha, NE (US); Jennifer C. Dant, Elkhorn, NE (US); Mark A. Mogler, Ames, IA (US); Steven M. Callister, Onalaska, WI (US); and Zhichang Xu, Omaha, NE (US)
Assigned to Intervet Inc., Rahway, NJ (US)
Appl. No. 16/767,715
Filed by Intervet Inc., Madison, NJ (US)
PCT Filed Dec. 3, 2018, PCT No. PCT/EP2018/083306 § 371(c)(1), (2) Date May 28, 2020, PCT Pub. No. WO2019/110486, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/594,342, filed on Dec. 4, 2017.
Prior Publication US 2020/0289634 A1, Sep. 17, 2020
Int. Cl. A61K 39/02 (2006.01); A61P 31/04 (2006.01); A61K 39/193 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0225 (2013.01) [A61K 39/0241 (2013.01); A61K 39/193 (2013.01); A61P 31/04 (2018.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01)]

17 Claims

1. An immunogenic composition comprising two or more alphavirus RNA replicon particles each individually encoding one or more Borrelia burgdorferi antigens;

wherein one alphavirus RNA replicon particle encodes a Borrelia burgdorferi outer surface protein A (OspA), wherein the OspA consists of the amino acid sequence of SEQ ID NO: 2,

and wherein another alphavirus RNA replicon particle encodes a Borrelia burgdorferi outer surface protein C (OspC), wherein the OspC consists of the amino acid sequence of SEQ ID NO: 4; wherein both OspA-borreliacidal and OspC-borreliacidal antibodies are induced in a canine when said canine is immunized with said immunogenic composition.